Page last updated: 2024-12-05

lorglumide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lorglumide is a synthetic non-peptide cholecystokinin (CCK) antagonist. Its synthesis involves the formation of a substituted benzamide derivative. Lorglumide binds to the CCK-A receptor, preventing the binding of the natural ligand CCK. This antagonistic action leads to the suppression of CCK-mediated effects, including the stimulation of pancreatic enzyme secretion, gallbladder contraction, and satiety. Lorglumide is studied for its potential therapeutic applications in various conditions, including pancreatitis, gastrointestinal disorders, and obesity. Its effects on pancreatic enzyme secretion make it a promising candidate for the treatment of pancreatitis. Furthermore, its ability to reduce appetite and food intake suggests potential in the management of obesity. However, its clinical use is limited due to its short duration of action and potential side effects, such as diarrhea and abdominal pain.'

lorglumide: RN given refers to (+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lorglumide : A racemate comprising equal amounts of (R)- and (S)-lorglumide. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-(3,4-dichlorobenzoyl)glutamic acid with the amino group of dipentylamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3960
CHEMBL ID24938
CHEBI ID88307
SCHEMBL ID149509
MeSH IDM0138779

Synonyms (52)

Synonym
BRD-A29854054-236-03-5
gtpl891
cr-1409
SPECTRUM_001628
PRESTWICK3_000915
BPBIO1_000870
pentanoic acid, 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-, (+-)-
ccris 6857
lorglumidum [latin]
lorglumida [spanish]
4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxopentanoic acid
d,l-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pentanoic acid
(+-)-4-(3,4-dichlorobenzamido)-n,n-dipentylglutaramic acid
lorglumide [inn]
PDSP2_000867
BSPBIO_000790
PRESTWICK2_000915
LOPAC0_000731
PDSP1_000881
lorglumide
KBIO2_004676
KBIO2_002108
KBIO2_007244
KBIOSS_002108
PRESTWICK1_000915
PRESTWICK0_000915
SPBIO_002979
HMS2090O20
CHEMBL24938 ,
chebi:88307 ,
L000350
97964-56-2
bdbm50008170
4-(3,4-dichloro-benzoylamino)-4-dipentylcarbamoyl-butyric acid
4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
lad1uq73be ,
unii-lad1uq73be
lorglumida
lorglumidum
(+/-)-4-(3,4-dichlorobenzamido)-n,n-dipentylglutaramic acid
pentanoic acid, 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-
dl-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxopentanoic acid
SCHEMBL149509
AB01275506-01
DTXSID2046961
n(2)-(3,4-dichlorobenzoyl)-n,n-dipentyl-alpha-glutamine
SBI-0050709.P002
4-(3,4-dichlorobenzamido)-5-(dipentylamino)-5-oxopentanoic acid
Q12745785
BRD-A29854054-236-07-6
SDCCGSBI-0050709.P003
pentanoic acid,4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxo-

Research Excerpts

Actions

ExcerptReferenceRelevance
"Lorglumide was able to inhibit the functional responses elicited by exogenous CCK administration in both pancreas, stomach and gallbladder, while deramciclane was not effective under such circumstances."( Effect of deramciclane, a new 5-HT receptor antagonist, on cholecystokinin-induced changes in rat gastrointestinal function.
Burghardt, B; Gacsályi, I; Kordás, K; Szénási, G; Varga, G, 1999
)
1.02

Treatment

Lorglumide pretreatment inhibited maternal behavior of LS vs SS group and potentiated the morphine-induced disruption of this behavior in all days of test (LM vs SM group) Pretreatment with lorgl Lumide blocked the reducing effect of P.

ExcerptReferenceRelevance
"Lorglumide pretreatment inhibited maternal behavior of LS vs SS group and potentiated the morphine-induced disruption of this behavior in all days of test (LM vs SM group)."( Puerperal blockade of cholecystokinin (CCK1) receptors disrupts maternal behavior in lactating rats.
Felicio, LF; Miranda-Paiva, CM; Nasello, AG; Yim, AJ,
)
0.85
"Pretreatment with lorglumide blocked the reducing effect of P."( Reducing effect of a Phaseolus vulgaris dry extract on food intake, body weight, and glycemia in rats.
Bombardelli, E; Cabras, C; Carai, MA; Colombo, G; Donzelli, F; Fantini, N; Gessa, GL; Lobina, C; Morazzoni, P; Riva, A, 2009
)
0.68
"Pretreatment with lorglumide (1.0 mg/kg ip), a selective CCK-A receptor antagonist, reversed CCK-induced inhibition of sucrose intake."( Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors.
Covasa, M; Hayes, MR; Savastano, DM, 2004
)
0.65
"Pretreatment with lorglumide, a CCK(1) receptor blocker, reversed the stimulation of amylase release produced by intraduodenal application of ghrelin."( The effect of luminal ghrelin on pancreatic enzyme secretion in the rat.
Jaworek, J; Konturek, SJ; Kot, M; Leja-Szpak, A; Macko, M; Mitis-Musioł, M; Nawrot-Porabka, K; Pawlik, WW; Szklarczyk, J, 2007
)
0.66
"pretreatment with lorglumide (0.1-10 pg) but not PD135,158 (1-100 pg) dose dependently reversed CCK's inhibition of the tail-flick response induced by CWSS."( Involvement of supraspinal and spinal CCK receptors in the modulation of antinociception induced by cold water swimming stress in the mouse.
Kim, KW; Kim, YH; Kwon, SH; Min, BH; Song, DK; Suh, HW, 1996
)
0.62
"Pretreatment with lorglumide caused a dose-dependent rightward shift of the dose-response curve, indicating competitive antagonism."( Cholecystokinin causes contraction of the pupillary sphincter in monkeys but not in cats, rabbits, rats and guinea-pigs: antagonism by lorglumide.
Almegård, B; Andersson, SE; Bill, A, 1990
)
0.81

Toxicity

ExcerptReferenceRelevance
" CR-1409 completely abolished the adverse effects of hydrocortisone on pancreatitis."( Involvement of cholecystokinin receptors in the adverse effect of glucocorticoids on diet-induced necrotizing pancreatitis.
Gomez, G; Green, D; Rajaraman, S; Thompson, JC; Townsend, CM; Uchida, T, 1989
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Both antagonists caused a rightward shift of the dose-response curve for CCK-8s on the monkey iris sphincter."( Cholecystokinin contracts isolated human and monkey iris sphincters; a study with CCK receptor antagonists.
Almegård, B; Bill, A; Stjernschantz, J, 1992
)
0.28
" CR 1409 caused a rightward and parallel shift in the dose-response curve of CCK-8-stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive mechanism of inhibition."( The effect of CR 1409, a potent CCK receptor antagonist, on basal and stimulated pancreatic secretion in rat.
Nagy, I; Pap, A; Takács, T; Varró, V, 1990
)
0.28
" The model was used to demonstrate a dose-response curve to bolus administration of exogenous cholecystokinin (0."( In vivo comparison of inhibition with proglumide and CR-1409 of cholecystokinin-induced pressure in the biliary tract of the guinea pig.
Hashimoto, T; MacLellan, DG; Poston, GJ; Thompson, JC; Townsend, CM; Upp, JR, 1990
)
0.28
"9 micrograms tetrodotoxin intracamerally had no clear effect on the dose-response relationship for CCK-8."( Cholecystokinin causes contraction of the pupillary sphincter in monkeys but not in cats, rabbits, rats and guinea-pigs: antagonism by lorglumide.
Almegård, B; Andersson, SE; Bill, A, 1990
)
0.48
" Schild analysis of the CCK dose-response curve indicates that L-364,718 and CR1409 exert their inhibitory effects on CCK-8-stimulated chief cell responses in a competitive manner."( Effects of CCK-receptor antagonists on CCK-stimulated pepsinogen secretion and calcium increase in isolated guinea pig gastric chief cells.
Konda, Y; Matozaki, T; Nagao, M; Nakano, O; Nishisaki, H; Sakamoto, C, 1990
)
0.28
" Biphasic dose-response curves to cholecystokinin for amylase release shifted to the right with an increase in the concentration of the drug."( CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini.
Iwamoto, Y; Kuzuya, T; Yamamoto, R, 1987
)
0.27
" The caerulein dose-response curve was gradually shifted to the right by increasing doses of CR 1409, indicating competitive-like kinetics."( Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.
Grendell, JH; Niederau, C; Niederau, M; Strohmeyer, G, 1989
)
0.28
" This rightward shift of the morphine dose-response curve was reversed by the intrathecal administration of either the CCKA receptor antagonist, lorglumide, or the CCKB receptor antagonist, PD135, 158."( Pentobarbital antagonism of morphine analgesia mediated by spinal cholecystokinin.
Fujimoto, JM; Lin, W; Rady, JJ, 1998
)
0.5
" Morphine analgesia was inhibited by dynorphin as shown by a rightward shift of the morphine dose-response curve."( Antianalgesic action of dynorphin A mediated by spinal cholecystokinin.
Fujimoto, JM; Holmes, BB; Rady, JJ, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
glutamic acid derivativeAn amino acid derivative resulting from reaction of glutamic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen by a heteroatom. The definition normally excludes peptides containing glutamic acid residues.
dicarboxylic acid monoamide
benzamides
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
D-Glutamine and D-Glutamate Metabolism1517
Peptidoglycan Biosynthesis I3036
Peptidoglycan Biosynthesis II3037

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cholecystokinin receptor type ARattus norvegicus (Norway rat)IC50 (µMol)0.03400.00000.43624.3000AID52912; AID53038
Cholecystokinin receptor type ARattus norvegicus (Norway rat)Ki0.12900.00010.27892.8900AID50500
Cholecystokinin receptor type ACavia porcellus (domestic guinea pig)IC50 (µMol)2.20000.00041.13803.5000AID52568
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID51292Ratio of IC50 against CCK-B1 and CCK-B(B2) binding1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID52568Inhibition of binding of [125I]- CCK-33 to guinea pig cortex1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID53038Inhibition of binding of [125I]- CCK-33 to rat pancreas1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID52912Concentration required to inhibit by 50% specific binding of [125I](BH)-CCK-8 to cholecystokinin type A receptor in rat pancreatic acini1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID51288Concentration required to inhibit by 50% the specific binding of [3H]pentagastrin to cholecystokinin type B receptor in rabbit gastric gland1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID50511Ratio between IC50 CCK-A vs IC50 CCK-B(B2)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID50966Inhibition of binding of [125I]gastrin to Cholecystokinin type B receptor from guinea pig gastric glands1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Novel glutamic acid derived cholecystokinin receptor ligands.
AID51443Inhibition of the specific binding of [125I](BH)-CCK-8 to Cholecystokinin type B receptor in rat brain cortex1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
AID50500Binding affinity against Cholecystokinin type A receptor using [125I](BH)-CCK-8 as radioligand in rat pancreas.1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
AID493017Wombat Data for BeliefDocking1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors.
AID1346809Rat CCK1 receptor (Cholecystokinin receptors)1990Proceedings of the National Academy of Sciences of the United States of America, Sep, Volume: 87, Issue:17
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
AID1346809Rat CCK1 receptor (Cholecystokinin receptors)1987Pancreas, , Volume: 2, Issue:1
CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini.
AID1346883Human CCK2 receptor (Cholecystokinin receptors)1996Neuropeptides, Aug, Volume: 30, Issue:4
Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (191)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (21.99)18.7374
1990's88 (46.07)18.2507
2000's43 (22.51)29.6817
2010's18 (9.42)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.72 (24.57)
Research Supply Index5.30 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.01%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other197 (98.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]